Theravance Biopharma Inc TBPH

NAS: TBPH | ISIN: KYG8807B1068   30/04/2025
9,770 USD (+2,84%)
(+2,84%)   30/04/2025

28 april 2025 · Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress · Persbericht

24 april 2025 · Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025 · Persbericht

7 april 2025 · Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting · Persbericht

31 maart 2025 · Theravance Biopharma to Participate in an Upcoming Investor Conference · Persbericht

27 maart 2025 · Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology · Persbericht

27 augustus 2024 · Theravance Biopharma to Participate in an Upcoming Investor Conference · Persbericht

5 augustus 2024 · Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update · Persbericht

25 juli 2024 · Theravance Biopharma to Participate in an Upcoming Investor Conference · Persbericht

22 juli 2024 · Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024 · Persbericht

13 mei 2024 · Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update · Persbericht

9 mei 2024 · Theravance Biopharma to Participate in an Upcoming Investor Conference · Persbericht

29 april 2024 · Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024 · Persbericht

10 april 2024 · Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024 · Persbericht

26 februari 2024 · Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update · Persbericht

22 februari 2024 · Theravance Biopharma to Participate in an Upcoming Investor Conference · Persbericht

14 februari 2024 · Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024 · Persbericht

5 januari 2024 · Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) · Persbericht

21 december 2023 · Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors · Persbericht

18 december 2023 · Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference · Persbericht

13 november 2023 · Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) · Persbericht

Mijn selecties